Kymera Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Return on Equity (ROE) Growth & History (KYMR)
Kymera Therapeutics's return on equity was −25.78% for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −25.78% | +10.60 pp |
| 2024 | 2024-12-31 | −36.38% | −3.18 pp |
| 2023 | 2023-12-31 | −33.21% | −0.61 pp |
| 2022 | 2022-12-31 | −32.60% | −5.64 pp |
| 2021 | 2021-12-31 | −26.96% | +16.57 pp |
| 2020 | 2020-12-31 | −43.53% | — |
Kymera Therapeutics quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −4.02% | +4.70 pp |
| Q1 2026 | 2026-03-31 | −4.44% | +3.65 pp |
| Q4 2025 | 2025-12-31 | −6.89% | +1.30 pp |
| Q3 2025 | 2025-09-30 | −8.57% | −0.65 pp |
| Q2 2025 | 2025-06-30 | −8.72% | −2.69 pp |
| Q1 2025 | 2025-03-31 | −8.09% | +0.69 pp |
| Q4 2024 | 2024-12-31 | −8.19% | −4.55 pp |
| Q3 2024 | 2024-09-30 | −7.92% | +4.80 pp |
| Q2 2024 | 2024-06-30 | −6.03% | +2.62 pp |
| Q1 2024 | 2024-03-31 | −8.78% | −0.18 pp |
| Q4 2023 | 2023-12-31 | −3.64% | +3.32 pp |
| Q3 2023 | 2023-09-30 | −12.72% | −3.28 pp |
| Q2 2023 | 2023-06-30 | −8.65% | +1.09 pp |
| Q1 2023 | 2023-03-31 | −8.60% | −0.34 pp |
| Q4 2022 | 2022-12-31 | −6.95% | +0.24 pp |
| Q3 2022 | 2022-09-30 | −9.44% | −1.73 pp |
| Q2 2022 | 2022-06-30 | −9.74% | −0.49 pp |
| Q1 2022 | 2022-03-31 | −8.26% | −3.58 pp |
| Q4 2021 | 2021-12-31 | −7.19% | −2.81 pp |
| Q3 2021 | 2021-09-30 | −7.71% | −0.46 pp |
| Q2 2021 | 2021-06-30 | −9.25% | — |
| Q1 2021 | 2021-03-31 | −4.68% | — |
| Q4 2020 | 2020-12-31 | −4.39% | — |
| Q3 2020 | 2020-09-30 | −7.25% | — |
Kymera Therapeutics return on equity trends
Over the last five fiscal years, Kymera Therapeutics's return on equity increased from −43.53% to −25.78%, a change of +17.75 percentage points. The latest reported quarter, Q2 2026, shows −4.02%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗